Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Zavicefta
Radiant Pharmaceuticals Ltd.
Generic: Ceftazidime + Avibactam
Medicine Overview of Zavicefta 2gm+0.5gm/Vial Injection
বাংলা
English
Indication
Intra-abdominal Infections, Urinary Tract Infections, Hospital-acquired and ventilator-associated bacterial pneumonia
Administration
IV Preparation Reconstitute powder with 10 mL of one of the following solutions Sterile water for injection 0.9% NaCl D5W All combinations of dextrose and sodium chloride injection containing up to 2.5% dextrose and 0.45% NaCl Lactated Ringer injection Upon constitution, solution may be held for no longer than 30 minutes before transferring and further diluting in a suitable infusion bag Additional dilution required Mix vial gently with 10 mL of a solution listed above Reconstituted solution results in ~0.167 g/mL of ceftazidime and ~0.042 g/mL avibactam Further dilute with the same diluent used for reconstitution (except sterile water for...
... Show moreAdult Dose
Intra-abdominal Infections Indicated in combination with metronidazole for complicated intra-abdominal infections (cIAIs) caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa 2.5 g (2 g/0.5 g) IV q8hr infused over 2 hr for 5-14 days Urinary Tract Infections Indicated for complicated urinary tract infections (cUTIs) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus mirabilis, and Pseudomonas aeruginosa 2.5 g (2 g/0.5 g) IV q8hr infused over 2 hr for 7-14 days Bacteria Pneumonia...
... Show moreChild Dose
<18 years: Safety and efficacy not established
Renal Dose
Renal impairment
CrCl >50 mL/min: No dose adjustment required
CrCl 31-50 mL/min: 1.25 g (1 g/0.25 g) IV q8hr
CrCl 16-30 mL/min: 0.94 g (0.75 g/0.19 g) IV q12hr
CrCl 6-15 mL/min: 0.94 g (0.75 g/0.19 g) IV q24hr
CrCl <5 mL/min: 0.94 g (0.75 g/0.19 g) IV q48hr
Patients on hemodialysis: Administer after hemodialysis on hemodialysis days
Contraindication
Known serious hypersensitivity to avibactam, ceftazidime, or other cephalosporins
Mode of Action
Ceftazidime: Third-generation cephalosporin with broad-spectrum gram-negative activity, including Pseudomonas; arrests bacterial growth by binding to 1 or more penicillin-binding proteins, and thereby inhibiting final transpeptidation step of peptidoglycan synthesis in bacterial cell-wall synthesis and inhibiting cell-wall biosynthesis
Avibactam: Diazabicyclooctanone, non-beta-lactam, beta-lactamase inhibitor; alone has no antibacterial activity at clinically relevant doses; when combined with ceftazidime, avibactam protects ceftazidime from degradation by beta-lactamase enzymes and effectively extends the antibiotic spectrum of ceftazidime to include many gram-negative bacteria normally not susceptible to ceftazidime
Precaution
Serious and occasionally fatal anaphylactic reactions and serious skin reactions have been reported with beta-lactam antibacterials; caution in patients with history of allergy to cephalosporins, penicillins, or carbapenems Clostridium difficile associated diarrhea (CDAD) has been associated with nearly all systemic antibacterials; severity may range from mild diarrhea to fatal colitis; may occur >2 months following antibacterial use; if CDAD suspected, manage fluid and electrolytes levels and monitor antibacterial treatment for CDAD Seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with ceftazidime, especially in the setting of renal impairment; adjust dose according to CrCl (see...
... Show moreSide Effect
1-10% (in cIAI plus metronidazole)
Diarrhea (8%)
Nausea (7%)
Vomiting (5%)
Headache (3%)
Dizziness (2%)
Abdominal pain (1%)
1-10% (in cUTI)
Diarrhea (3%)
Nausea (3%)
Constipation (2%)
Upper abdominal pain (1%)
1-10% (in HABP/VABP)
Nausea (3%)
Pruritus (2%)
Frequency Not Reported
Blood and lymphatic disorders: Thrombocytopenia, thrombocytosis, leukopenia
General disorders and administration site conditions: Injection site phlebitis
Infections and infestations: Candidiasis
Investigations:Increased aspartate aminotransferase, increased alanine aminotransferase, increased gamma-glutamyltransferase
Metabolism and nutrition disorders: Hypokalemia
Nervous system disorders: Dysgeusia
Renal and urinary disorders: Acute kidney injury, renal impairment, nephrolithiasis
Skin and subcutaneous tissue disorders: Rash, rash maculopapular, urticaria
Psychiatric disorders: Anxiety
Pregnancy Category Note
Pregnancy There are no adequate and well-controlled studies of ceftazidime/avibactam, ceftazidime, or avibactam in pregnant women Neither ceftazidime nor avibactam were teratogenic in rats at doses 40 and 9 times the recommended human clinical dose; in the rabbit, at twice the exposure as seen at the human clinical dose, there were no effects on embryofetal development with avibactam Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed Lactation Ceftazidime is excreted in human milk in low concentrations Unknown whether avibactam is excreted into human milk, although avibactam...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
